Abstract
1α, 25‑dihydroxyvitamin D3 (1,25‑D3), an active vitamin D metabolite, is a well‑known regulator of osteogenic differentiation. However, how 1,25‑D3 regulates osteogenic differentiation in human periodontal ligament stem cells (hPDLSCs) remains to be fully elucidated. The present study aimed to clarify this issue through well‑controlled in vitro experiments. After hPDLSCs were treated with 1,25‑D3, immunofluorescence and western blotting were used to detect the expression of vitamin D receptor; Cell Counting Kit‑8 and western blotting were used to assay the cell proliferation ability. Alkaline phosphatase staining, Alizarin Red staining and western blotting were used to detect the osteogenic differentiation. It was found that treating hPDLSCs with 1,25‑D3: i) Inhibited cell proliferation; ii) promoted osteogenic differentiation; iii) upregulated the expression of transcriptional coactivator with PDZ‑binding motif (TAZ), an important downstream effector of Hippo signaling that has been demonstrated to be involved in the osteogenic differentiation of stem/progenitor cells; and iv) that co‑treatment of TAZ‑overexpressing hPDLSCs with 1,25‑D3 synergistically stimulated the expression of osteogenic markers. These results suggested that the induction of osteogenic differentiation promoted by 1,25‑D3 in hPDLSCs involves, at least in part, the action of TAZ.